103429-32-9

Basic information

• Product Name: CTAP
• Synonyms: H-D-PHE-CYS-TYR-D-TRP-ARG-THR-PEN-THR-NH2;D-PHE-CYS-TYR-D-TRP-ARG-THR-PEN-THR-NH2;CTAP;CYS2, TYR3, ARG5, PEN7-AMIDE;H-D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(Cys2-Pen7);M.W. 1104.30 C51H69N13O11S2;CTAP-NH2;D-Phe-L-Cys-L-Tyr-D-Trp-L-Arg-L-Thr-L-Pen-L-Thr-NH2
• CAS NO: 103429-32-9
• Molecular Formula: C₅₁H₆₉N₁₃O₁₁S₂
• Molecular Weight: 1104.3
• Product Categories: Peptide;Neuropeptides;Opioid Peptides;Other Opioid Peptides;Other Opioid PeptidesPeptides for Cell Biology;Opioid receptor and opioid-like receptor
• Mol File: 103429-32-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.49 g/cm³
• Storage Temp.: −20°C
• CAS DataBase Reference: CTAP(CAS DataBase Reference)
• NIST Chemistry Reference: CTAP(103429-32-9)
• EPA Substance Registry System: CTAP(103429-32-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 103429-32-9(Hazardous Substances Data)

Usage

Description

CTAP, also known as [Phe-Phe-Gln-Asn-Pen-Pen]-NH2, is a synthetic peptide derived from the N-terminal sequence of the human thyrotropin-releasing hormone (TRH). It is a selective μ-opioid receptor (MOR) antagonist with various applications in the regulation of aggressive behavior, sodium appetite, and pain management.

Uses

Used in Pharmaceutical Industry:
CTAP is used as a μ-opioid receptor antagonist for the regulation of aggressive behavior in mammals. It targets the central nucleus of the amygdala, which is responsible for controlling sodium appetite and regulating sodium intake.
Used in Pain Management:
CTAP is used as a μ-opioid receptor antagonist to study the anti-hyperalgesic effect of dipeptidyl peptidase 4 (DPP4) inhibitor isoleucine-proline-isoleucine (IPI) and vildagliptin in carrageenan-induced inflammation. This application helps in understanding the role of MOR in pain management and the potential of CTAP in treating pain-related conditions.
Used in Neurological Research:
CTAP is used as a μ-opioid receptor antagonist to study the role of MOR in glutamate and gamma-aminobutyric acid (GABA) efflux during predator stress in rats. This research contributes to the understanding of the neurochemical mechanisms underlying stress responses and the potential therapeutic applications of CTAP in stress-related disorders.
Used in Endogenous Opioid Peptide Research:
CTAP is used as a μ-opioid receptor antagonist to determine the endogenous opioid peptide involved in blocking pain induced by activated gastrin-releasing peptide (Grp+) neurons. This application aids in the identification of specific endogenous opioid peptides and their roles in pain modulation, potentially leading to the development of novel pain management strategies.

Biochem/physiol Actions

CTAP is a peptide antagonist produced from somatostatin analogs.

Upstream product

• 13836-37-8 N^α-Boc-N^G-tosyl-L-arginine 
• 15260-10-3 N-Boc-O-benzyl-L-threonine 
• 104323-41-3 N^α-Boc-L-Pen(S-4'-methylbenzyl) 
• 5241-64-5 Boc-D-Trp-OH 
• 13836-37-8 Boc-Arg(Tos)-OH 
• 863443-56-5 D-Phe-L-Cys-L-Tyr-D-Trp-L-Arg-L-Thr-L-Pen-L-Thr-NH₂ 

Relevant articles and documents

Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays

Topographically constrained analogues of the highly μ-opioid-receptor- selective antagonist CTAP (H-D-Phe-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2, 1) were prepared by solid-phase peptide synthesis. Replacement of the D-Phe residue with conformatio